Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Rekombinanter MS4A1 (Rituximab Biosimilar) Antikörper

Der Maus-Monoklonal Anti-MS4A1 (Rituximab Biosimilar)-Antikörper wurde für FACS und in vivo validiert. Er ist geeignet zum Nachweis von MS4A1 (Rituximab Biosimilar) in Proben aus Human. }
Produktnummer ABIN7200660
-15% Promotion 2026
187,98 €
221,15 €
Sparen Sie 33,17 € (-15 %)
Zzgl. Versandkosten 20,00 € und MwSt
Lieferung nach: Deutschland
Lieferung in 7 bis 9 Werktagen

Kurzübersicht für Rekombinanter MS4A1 (Rituximab Biosimilar) Antikörper (ABIN7200660)

Target

MS4A1 (Rituximab Biosimilar)

Antikörpertyp

Recombinant Antibody

Reaktivität

  • 8
  • 2
  • 2
Human

Wirt

  • 3
  • 3
  • 1
  • 1
Maus

Klonalität

  • 5
  • 3
Monoklonal

Konjugat

  • 8
Dieser MS4A1 (Rituximab Biosimilar) Antikörper ist unkonjugiert

Applikation

  • 6
  • 2
  • 1
  • 1
  • 1
  • 1
Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse

Research Grade

Klon

10F381
  • Verwendungszweck

    Rituximab Biosimilar, CD20 Monoclonal Antibody

    Spezifität

    The monoclonal antibody rituximab biosimilar specifically binds to the human TNF alpha.

    Produktmerkmale

    B-lymphocyte antigen CD20 encoded by the MS4A1 gene is an activated-glycosylated phosphoprotein on the surface of all B-cells. The function of the membrane protein is to stimulate B-cell immune response, specifically against T-independent antigens though its natural ligand remains unknown. CD20 is important for the development and differentiation of B-cells into plasma cells. CD20 belongs to the membrane-spanning 4A family with common structural features, similar intron/exon splice boundaries, and unique expression patterns among hematopoietic cells and nonlymphoid tissues. Rituximab, a chimeric anti-CD20 monoclonal antibody, destroys B cells and is used to treat diseases with excessive numbers of B cells, overactive B cells, or dysfunctional B cells, such as many lymphomas, leukemias, transplant rejection, and autoimmune disorders.

    Aufreinigung

    Protein A or G affinity column

    Reinheit

    >95 % by reducing SDS-PAGE

    Sterilität

    0.2 μm filtered

    Endotoxin-Niveau

    < 1 EU per 1 mg of the protein by the LAL method

    Immunogen

    The monoclonal antibody rituximab biosimilar was produced in the Rituximab biosimilar CHO stable cell line.

    Isotyp

    IgG1
  • Applikationshinweise

    ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by rituximab.

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Format

    Liquid

    Konzentration

    > 3 mg/mL

    Buffer

    PBS, pH 7.4, no stabilizers or preservatives.

    Konservierungsmittel

    Without preservative

    Lagerung

    4°C,-20 °C

    Informationen zur Lagerung

    12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

    Haltbarkeit

    12 months
  • Target

    MS4A1 (Rituximab Biosimilar)

    Andere Bezeichnung

    Rituximab Biosimilar

    Substanzklasse

    Biosimilar
Sie sind hier:
Chat with us!